Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma.

Wong, Madeline M F; Lye, Munn-Sann; Cheng, Hwee-Ming; Sam, Choon-Kook.
Asian Pac J Allergy Immunol ; 2005 Mar; 23(1): 65-7
Artículo en Inglés | IMSEAR | ID: sea-36795

Documentos relacionados

  1. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma.
  2. Antibody Profiling of Pan-Cancer Viral Proteome Reveals Biomarkers for Nasopharyngeal Carcinoma Diagnosis and Prognosis.
  3. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
  4. Diagnostic value of the Epstein-Barr virus serological markers in patients with nasopharyngeal carcinoma in cases of undetectable primary tumor location.
  5. Combining Epstein-Barr virus antibodies for early detection of nasopharyngeal carcinoma: A meta-analysis.
  6. Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology.
  7. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
  8. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
  9. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.
  10. Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer.